RE:RE:RE:My goodness..My view is simple. A company entering a Phase 3B trial with BTD in a massive indication, and frankly quite good results in previous 'failed' trials... such a company may be off the radar of the average retail investor, but it is not off the radar of major BP companies who need to replenish their pipelines with upcoming new drugs.
We should be careful not to think RVX is the only company in need. The biggest BP's have need of a company like RVX. Their Executives need to show their shareholders they can spot a new drug before it is approved for commercialization, and we are extremely close.
I have even wondered, with a major partner on board, could the 3B trial be swapped out for a Phase 4 trial and immediate commercialization, given our fantastic safety record? Clearly we would need a major partner to manage monitoring of Phase 4 results.
The current share price will have no relationship to the future share price if a major partner steps in.
For anyone who believed a buyout could happen years ago, would you not think some BP wouild be far more interested now?
J4P